We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI-Enabled Technology to Help Global Molecular Imaging Market Reach USD 11.13 Billion by 2028

By LabMedica International staff writers
Posted on 10 Sep 2019
The global molecular imaging market was estimated at USD 6.84 billion in 2018 and is projected to grow at a CAGR of 5.03% during the forecast period 2019-2028 to reach USD 11.13 billion by 2028. More...
The market growth will be driven by significant developments in the field of multimodality and optical imaging, particularly the emergence of AI-enabled imaging technology.

These are the latest findings of Research and Markets, Inc. (Fremont CA, USA), a global B2B market intelligence and advisory firm.

Within the past few decades, the medical imaging industry has been witnessing significant technological advancements. Currently, the demand for preventive care and early diagnosis is rising due to the increasing incidence of chronic disorders. As a result, several manufacturers in the market are identifying novel methods of disease detection, including molecular imaging, which is currently the most important development.

Since the past few years, the market has been witnessing an increased demand for molecular imaging technologies such as PET, SPECT, and multimodality imaging due to rising awareness as well as increasing number of government initiatives to promote the early detection of diseases using molecular imaging. However, ongoing technological advancements such as the launch of next generation of SPECT cameras containing cadmium zinc telluride (CZT) detectors and the emergence of AI-enabled imaging technology is expected to further aid the market growth during the forecast period.

The advent of multimodality imaging technology has led to increased adoption of PET-CT, PET-MRI, SPECT-CT, and related procedures in routine practice. Currently, the oncology application-specific molecular imaging segment is expected to be the major contributor to the molecular imaging market. The launch of novel contrast agents is expanding the scope of application of molecular imaging while small molecule-based imaging agents hold a major share of the molecular imaging market.

Geographically, North America currently leads the global molecular imaging market and was valued at USD 3.89 billion in 2018. The increasing demand for minimally invasive surgeries, rising cases of chronic diseases, approval of novel radiotracers, and growing awareness of molecular imaging are driving the growth of the North American molecular imaging market. However, the Asia-Pacific molecular imaging market is expected to register the highest CAGR of 6.68% during the forecast period.

Related Links:
Research and Markets

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Thyroid Test
Anti-Thyroid EIA Test
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.